Ovoca Bio appoints new chief business officer

(Sharecast News) - Women's health-focussed biopharmaceuticals company Ovoca Bio announced the appointment of Christopher Wiltshire as its chief business officer and executive director of the board on Friday, effective immediately.
The AIM-trade firm said Wiltshire previously served as a non-executive director on its board.

It described Wiltshire as an "experienced" senior pharmaceutical and biotechnology executive with more than 25 years of international experience.

He currently serves as the chief executive officer of Hematherix, which is developing a recombinant clotting factor, and is the former head of business development and licensing at the Nasdaq-listed La Jolla Pharmaceutical.

Wiltshire also has a consultancy practice, which provides strategic advice to early and mid-stage biotechnology and pharmaceutical companies.

Ovoca added that he previously served in a number of senior positions at Pfizer, including as head of business transactions and investments within 'The Pfizer Incubator'.

Wiltshire holds an MA in Engineering from the University of Cambridge, and an MBA from the Darden Graduate School at the University of Virginia.

As chief business officer, Ovoca said he would have a "key role" in delivering its long-term vision of becoming a leader in the development and commercial partnering of novel medicines in areas of high unmet need that affect women, in particular through the ongoing clinical development of its novel treatment for premenopausal women suffering from hypoactive sexual desire disorder, 'BP-101'.

"Christopher has significant global pharmaceutical industry experience and has contributed greatly to the strategic direction of Ovoca Bio as a non-executive director," said chief executive officer Kirill Golovanov.

"We are delighted to welcome him as full time CBO and executive director.

"His appointment comes at an exciting time for the business as we seek to ramp up clinical development activities for our lead asset, BP-101, in major global markets."

At 1230 BST, shares in Ovoca Bio were down 1.54% at 9.6p.